AI adoption in clinical development is high- AI impact is not.
Across the industry, GenAI and LLM pilots show early success, but stall when organizations attempt to scale them into regulated, end-to-end clinical workflows. The result is a growing gap between AI investment and real operational value.
This whitepaper examines why nearly 95% of AI initiatives fail in clinical development, and why solving this problem requires more than better models or larger pilots.
Why Download This Whitepaper:
This paper is intended for leaders responsible for delivery, quality, and compliance. It provides:
- A clear explanation of why most GenAI and LLM initiatives fail after the pilot stage
- Insight into where AI delivers meaningful value in clinical development today
- A practical view of how Agentic AI works across protocols, studies, data, and documentation
- Early evidence of measurable impact, including cost, time, and quality improvements
- A framework for adopting AI at scale without increasing regulatory risk